Study details
Enrolling now
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
EpiBiologics
NCT IDNCT07462377ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Ages
18+
Locations
5 sites in CA, NJ, TN +1
About this study
This Phase 1 study is focused on people with egfr. The primary outcome being measured is Evaluation of the safety and tolerability of EPI-326.
Based on ClinicalTrials.gov records.
PhasePhase 1
Primary goalEvaluation of the safety and tolerability of EPI-326
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low7%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Evaluation of the safety and tolerability of EPI-326
Secondary: Determination of area under the concentration-time curve (AUC), Determination of clearance (CL) from the blood, Determination of maximum (Cmax) and minimum (Cmin) plasma concentration, Duration of response (DOR), Objective response rate (ORR)
Body systems
Oncology, Respiratory